{
    "clinical_study": {
        "@rank": "4817", 
        "arm_group": [
            {
                "arm_group_label": "PA21", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Sevelamer hydrochloride", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of PA21 in hemodialysis\n      patients with hyperphosphatemia"
        }, 
        "brief_title": "A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia", 
        "condition": [
            "Hemodialysis", 
            "Hyperphosphatemia"
        ], 
        "condition_browse": {
            "mesh_term": "Hyperphosphatemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients age 20 or older, regardless of gender.\n\n          -  Receiving stable maintenance hemodialysis 3 times a week.\n\n          -  Patients not having changed their phosphate binder agent dose, for 4 weeks or more\n             before their observation period start.\n\n        Exclusion Criteria:\n\n          -  Patients having history of a pronounced brain / cardiovascular disorder.\n\n          -  Patients having severe gastrointestinal disorders.\n\n          -  Patients having severe hepatic disorders."
            }, 
            "gender": "Both", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "firstreceived_date": "May 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01850602", 
            "org_study_id": "PA1301"
        }, 
        "intervention": [
            {
                "arm_group_label": "PA21", 
                "intervention_name": "PA21", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sevelamer hydrochloride", 
                "intervention_name": "Sevelamer hydrochloride", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sevelamer"
        }, 
        "keyword": [
            "Hemodialysis", 
            "Hyperphosphatemia"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tokyo and Other Japanese City", 
                    "country": "Japan"
                }
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Serum phosphate concentrations", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01850602"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in serum calcium concentrations", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Change from baseline in serum calcium \u00d7 phosphate product", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Change from baseline in serum intact-PTH concentrations", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Kissei Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kissei Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}